Go with the flow...

- Last updated on GMT

A series of new flow cytometry products will soon hit the market
with the announcement yesterday from US companies BD Biosciences
and Molecular Probes that, following a recent license agreement, BD
Biosciences Pharmingen has launched a series of products
incorporating Molecular Probes' Alexa Fluor dye technology.

A series of new flow cytometry products will soon hit the market with the announcement yesterday from US companies BD Biosciences and Molecular Probes that, following a recent license agreement, BD Biosciences Pharmingen has launched a series of products incorporating Molecular Probes' Alexa Fluor dye technology.

The company claims that use of this fluorophore technology will provide researchers using its flow cytometry systems with increased capabilities to explore cellular diversity and function.

"The addition of these fluorophores from Molecular Probes greatly enhances our ability to provide a flexible and comprehensive toolbox for biological analyses, extending the power of multi-parameter flow cytometry to 13-colour cell analysis,"​ said Kip Miller, vice president and general manager of BD Biosciences Pharmingen​. "In addition, these dyes will enhance our product offering for our high-content BD FACSArray bioanalyzer, which is scheduled for release this summer."

The Alexa Fluor dyes are a family of spectrally distinct, highly fluorescent, very soluble, and photostable dyes that provide enhanced sensitivity for critical applications, such as detecting signalling events occurring within individual cells in complex cellular populations.

The two companies hope that the combination of BD Biosciences technology and the Alexa Fluor dyes from Molecular Probes will provide a powerful approach to creating new avenues for multiplex analysis to facilitate drug discovery.

"This agreement with BD Biosciences exemplifies our strategy of partnering with technology and market leaders to drive the development of high value applications for fluorescence detection solutions,"​ said Anthony Martin, president and chief executive officer of Molecular Probes.

Related topics: Preclinical Research

Follow us

Products

View more

Webinars